126 - Evolving Hepatitis B Treatment Guidelines and Implications on Practice: A Case-Based Panel Discussion

Friday, October 18, 2024

10:30 AM – 11:45 AM US PT

Location: 515 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Michael Melia, MD (he/him/his)

ID Fellowship Program Director
Johns Hopkins University
Baltimore, MD, United States

Interactive Moderator(s)

Debika Bhattacharya, MD MSc

Clinical Professor
Medicine
David Geffen School of Medicine, University of California, Los Angeles; Division of Infectious Diseases, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California
Los Angeles, CA, United States
Su Wang, MD, MPH, FACP (she/her/hers)

Medical Director, Viral Hepatitis Programs & Center for Asian Health| Global Health Advisor
Center for Asian Health & Liver Center
Cooperman Barnabas Medical Center | Hepatitis B Foundation
Florham Park, NJ, United States

Slides

Panelist(s)

H. Nina Kim, MD, MSc (she/her/hers)

Professor
Division of Allergy and Infectious Diseases
University of Washington
Seattle, WA, United States
Susanna Naggie, MD, MHS (she/her/hers)

Vice Dean for Clinical Research; Director of Duke Clinical and Translational Sciences Institute; Professor of Medicine
Duke University; Duke Clinical Research Institute
Durham, NC, United States
Mark Sulkowski, MD (he/him/his)

Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD, United States

Disclosure(s):

Michael T. Melia, MD: No financial relationships to disclose

Debika Bhattacharya, MD MSc: Gilead Sciences, Inc.: Grant/Research Support (Ongoing)

Su H. Wang, MD, MPH, FACP: Gilead Sciences, Inc: Grant/Research Support (Ongoing)

H. Nina Kim, MD, MSc: Gilead: Grant/Research Support (Ongoing)

Susanna Naggie, MD, MHS: BMS/PRA: Event Adjudication (Ongoing); PHI: DSMB (Ongoing); Vir Biotechnology: Stocks/Bonds (Public Company) (Ongoing)

Mark S. Sulkowski, MD: AbbVie: Advisor/Consultant (); Aligos Therapeutics: Advisor/Consultant (); Gilead: Advisor/Consultant (); GSK: Advisor/Consultant (), Grant/Research Support (); Janssen: Grant/Research Support (); Precision Biosciences: Advisor/Consultant (); Vir: Grant/Research Support (); Virion: Advisor/Consultant ()

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify non-invasive tests recommended for establishment of significant fibrosis or cirrhosis;
describe patients for whom hbv treatment is recommended;
indicate preferred agents for hbv treatment in patients with and without impaired renal function and osteoporosis;
analyze the recommendations for antiviral prophylaxis for pregnant persons.